Recombinant Proteins iso9001 ISO13485
搜索
 > 【B7-1】重组蛋白信息

B7-1信息

英文名称:Cluster of differentiation 80
中文名称:分化群80
靶点别称:Activation B7-1 antigen,LAB7,T-lymphocyte activation antigen CD80,CD80 Molecule,CD80 Antigen (CD28 Antigen Ligand 1, B7-1 Antigen),B-Lymphocyte Activation Antigen B7,CTLA-4 Counter-Receptor B7.1,CD28LG1,BB1,Costimulatory Molecule Variant IgV-CD80,Costimul
上市药物数量:2
临床药物数量:3
最高研发阶段:批准上市

B7-1产品列表

 
评论(2)
B71-H5228|Human B7-1 / CD80 Protein, His Tag
  1. 182XXXXXXX2
  2. 2人赞
  3. 运用Acro家的B7-1与别家的CD28做BIL实验,亲和力不错,拟合结果相当好,R2达到了0.997,不错的产品。
  4. >
  5. 2020-01-10
B71-H5228|Human B7-1 / CD80 Protein, His Tag
  1. 152XXXXXXX2
  2. 3人赞
  3. 使用过该蛋白做ELISA实验,将该CD80蛋白包被到孔板中,然后加入抗体分子与biotin-PDL1做blocking assay,可以获得理想的数据。
  4. >
  5. 2019-10-12
 

B7-1 分子别名

CD80,B7,B7-1,B7.1,BB1,CD28LG,CD28LG1,LAB7

B7-1 分子背景

B7-1 and B7-2, together with their receptors CD28 and CTLA­4, constitute one of the dominant co-stimulatory pathways that regulate T­ and B­cell responses. Although both CTLA­4 and CD28 can bind to the same ligands, CTLA­4 binds to B7­1 and B7­2 with a 20 ­ 100 fold higher affinity than CD28 and is involved in the down­regulation of the immune response. B-lymphocyte activation antigen B7-1 (referred to as B7) also known as cluster of Differentiation 80 (CD80), is a member of cell surface immunoglobulin superfamily and is expressed on activated B cells, activated T cells, macrophages and dendritic cells. It is the ligand for two different proteins on the T cell surface: CD28 (for autoregulation and intercellular association) and CTLA-4 (for attenuation of regulation and cellular disassociation). CD80 works in tandem with CD86 to prime T cells. CD80 plays a role in induction of innate immune responses by activating NF-κB-signaling pathway in macrophages. CD80 is thus regarded as promising therapeutic targets for autoimmune diseases and various carcinomas.

B7-1 参考文献

B7-1上市药物信息

英文名称 中文名称 研发代码 研发阶段 公司 最早商品名 最早批准国家 最早适应症 最早批准公司 最早批准日期 适应症 临床试验
Belatacept LEA29Y; LEA-029; BMS-224818; L104EA29YIg 批准上市 百时美施贵宝 Nulojix EU 肾脏移植排斥 Bristol-Myers Squibb Pharma Eeig 2011-06-15 肾脏移植排斥, 器官移植排斥 详情
Abatacept 阿巴西普 BMS-188667; BMS-188667SC; ONO-4164SC; ONO-4164 批准上市 百时美施贵宝 Orencia Mainland China 类风湿关节炎 Bristol-Myers Squibb Company 2005-12-23 多发性硬化, 克罗恩病, 肾病综合征, 肌病, 溃疡性结肠炎, 银屑病关节炎, 局灶性节段性肾小球硬化症, 系统性红斑狼疮, 银屑病, 多发性肌炎, 微小病变性肾病, 狼疮肾炎, 幼年型类风湿性关节炎, Sjtoegren综合征, 类风湿关节炎, 新型冠状病毒肺炎, 皮肌炎, 巨细胞性动脉炎 详情

B7-1临床药物信息

英文名称 研发代码 研发阶段 公司 适应症 临床试验
Chimeric antigen receptor T-cell therapy (Hunan Zhaotai Yongren Biotech) Z-CTLs 临床一期 湖南昭泰涌仁医疗创新有限公司 非小细胞肺癌
rVV-740CTA vaccine (University Hospital Basel) rVV-740CTA 临床一期 University Hospital Basel 乳腺癌 详情
Belatacept biosimilar (Alphamab) KN-019 临床二期 苏州康宁杰瑞生物科技有限公司 肾脏移植排斥, 类风湿关节炎, 自身免疫疾病 详情

消息提示

请输入您的联系方式,再点击提交!

确定